CRISPR Technology in Cancer Diagnosis and Treatment: Opportunities and Challenges

被引:9
作者
Shademan, Behrouz [1 ]
Masjedi, Sepideh [2 ]
Karamad, Vahidreza [1 ]
Isazadeh, Alireza [3 ]
Sogutlu, Fatma [1 ]
Rad, Mohammad Hosein Saeedi [4 ]
Nourazarian, Alireza [5 ]
机构
[1] EGE Univ, Fac Med, Dept Med Biol, Izmir, Turkey
[2] Islamic Azad Univ, Dept Cellular & Mol Biol Sci, Tonekabon Branch, Tonekabon, Iran
[3] Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz, Iran
[4] Shahid Beheshti Univ Med Sci, Dept Biol, Tehran, Iran
[5] Khoy Univ Med Sci, Dept Basic Med Sci, Khoy, Iran
关键词
CRISPR; Gene editing; Cancer treatment; Solid tumors; IN-VIVO; COLORECTAL-CANCER; LUNG-CANCER; CHROMOSOMAL TRANSLOCATIONS; TUMOR-SUPPRESSOR; DNA METHYLATION; GENE-EXPRESSION; HUMAN-CELLS; GENOME; CAS;
D O I
10.1007/s10528-022-10193-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A novel gene editing tool, the Cas system, associated with the CRISPR system, is emerging as a potential method for genome modification. This simple method, based on the adaptive immune defense system of prokaryotes, has been developed and used in human cancer research. These technologies have tremendous therapeutic potential, especially in gene therapy, where a patient-specific mutation is genetically corrected to cure diseases that cannot be cured with conventional treatments. However, translating CRISPR/Cas9 into the clinic will be challenging, as we still need to improve the efficiency, specificity, and application of the technology. In this review, we will explain how CRISPR-Cas9 technology can treat cancer at the molecular level, focusing on ordination and the epigenome. We will also focus on the promise and shortcomings of this system to ensure its application in the treatment and prevention of cancer.
引用
收藏
页码:1446 / 1470
页数:25
相关论文
共 133 条
  • [1] C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector
    Abudayyeh, Omar O.
    Gootenberg, Jonathan S.
    Konermann, Silvana
    Joung, Julia
    Slaymaker, Ian M.
    Cox, David B. T.
    Shmakov, Sergey
    Makarova, Kira S.
    Semenova, Ekaterina
    Minakhin, Leonid
    Severinov, Konstantin
    Regev, Aviv
    Lander, Eric S.
    Koonin, Eugene V.
    Zhang, Feng
    [J]. SCIENCE, 2016, 353 (6299)
  • [2] Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing
    Alves, Eric
    Taifour, Shahama
    Dolcetti, Riccardo
    Chee, Jonathan
    Nowak, Anna K.
    Gaudieri, Silvana
    Blancafort, Pilar
    [J]. MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2021, 21 : 592 - 606
  • [3] Cancer is a Preventable Disease that Requires Major Lifestyle Changes
    Anand, Preetha
    Kunnumakara, Ajaikumar B.
    Sundaram, Chitra
    Harikumar, Kuzhuvelil B.
    Tharakan, Sheeja T.
    Lai, Oiki S.
    Sung, Bokyung
    Aggarwal, Bharat B.
    [J]. PHARMACEUTICAL RESEARCH, 2008, 25 (09) : 2097 - 2116
  • [4] [Anonymous], 2019, NPJ PRECIS ONCOL, V3, p1 1 8
  • [5] Progranulin and its biological effects in cancer
    Arechavaleta-Velasco, Fabian
    Eduardo Perez-Juarez, Carlos
    Gerton, George L.
    Diaz-Cueto, Laura
    [J]. MEDICAL ONCOLOGY, 2017, 34 (12)
  • [6] Viral gene therapy for breast cancer: progress and challenges
    Asad, Antonela S.
    Moreno Ayala, Mariela A.
    Florencia Gottardo, M.
    Zuccato, Camila
    Nicola Candia, Alejandro Javier
    Zanetti, Flavia A.
    Seilicovich, Adriana
    Candolfi, Marianela
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (08) : 945 - 959
  • [7] In Vivo CRISPR/Cas9 Gene Editing Corrects Retinal Dystrophy in the S334ter-3 Rat Model of Autosomal Dominant Retinitis Pigmentosa
    Bakondi, Benjamin
    Lv, Wenjian
    Lui, Bin
    Jones, Melissa K.
    Tsai, Yuchun
    Kim, Kevin J.
    Levy, Rachelle
    Akhtar, Aslam Abbasi
    Breunig, Joshua J.
    Svendseni, Clive N.
    Wang, Shaomei
    [J]. MOLECULAR THERAPY, 2016, 24 (03) : 556 - 563
  • [8] CRISPR provides acquired resistance against viruses in prokaryotes
    Barrangou, Rodolphe
    Fremaux, Christophe
    Deveau, Helene
    Richards, Melissa
    Boyaval, Patrick
    Moineau, Sylvain
    Romero, Dennis A.
    Horvath, Philippe
    [J]. SCIENCE, 2007, 315 (5819) : 1709 - 1712
  • [9] Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs)
    Beltran, Adriana S.
    Blancafort, Pilar
    [J]. EPIGENETICS, 2011, 6 (02) : 224 - 235
  • [10] Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma
    Benamar, Mouadh
    Guessous, Fadila
    Du, Kangping
    Corbett, Patrick
    Obeid, Joseph
    Gioeli, Daniel
    Slingluff, Craig L., Jr.
    Abbas, Tarek
    [J]. EBIOMEDICINE, 2016, 10 : 85 - 100